Physician

Christopher Melvin Lee, M.D.

According to 2025 Medicare claims, Christopher Lee, M.D. (NPI: 1043266810) practices radiation oncology in the Spokane-Spokane Valley, WA market, with the plurality of this provider's patient population coming from Spokane, WA. This provider's primary affiliated billing organization is CANCER CARE NORTHWEST CENTERS P S (NPI: 1922072081; TIN: 911007627) and primary practice location at 99202-1311. Lee is affiliated with the Kootenai Accountable Care, LLC (ACO ID: A3621), Caravan Collaborative Pathways (ACO ID: A4604), and Collaborative ACO 30, LLC (ACO ID: A5483), participating under the MSSP model.

Lee's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 775 traditional Medicare patients, billed 20,382 HCPCS/CPT codes, and received $1,687,914 in Medicare payments. The top billing code was 78815 (Nuclear medicine study from skull base to mid-thigh with ct scan). Part D data shows 178 prescription claims across 73 beneficiaries totaling $179,047 in drug costs, led by Orgovyx (Relugolix). DME data shows 25 claims. Open Payments data shows 59 records totaling $36,742. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have risen steadily, from $6,333 to $179,047. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	680	41,449	$1,203,045
2016	749	48,965	$1,136,016
2017	836	32,944	$1,228,943
2018	843	35,717	$1,408,661
2019	836	30,165	$1,488,510
2020	754	24,981	$1,462,613
2021	810	25,434	$1,562,208
2022	829	25,729	$1,644,201
2023	817	22,048	$1,748,756
2024	775	20,382	$1,687,914

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	82	153	$6,333
2016	74	165	$7,707
2017	57	116	$15,714
2018	64	181	$4,947
2019	67	169	$4,746
2020	71	164	$3,350
2021	70	191	$4,754
2022	62	163	$87,413
2023	61	164	$206,755
2024	73	178	$179,047

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	58	$11,948
2016	N/R	92	$13,994
2017	N/R	35	$4,252
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	13	$562
2021	N/R	28	$835
2022	N/R	67	$149,338
2023	N/R	42	$4,198
2024	N/R	25	$1,022

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
78815	Nuclear medicine study from skull base to mid-thigh with ct scan	272	328	$1,209
A9552	Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries	277	334	$277
77014	Ct guidance for insertion of radiation therapy fields	137	1,055	$95
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	136	182	$62
36415	Insertion of needle into vein for collection of blood sample	146	199	$9

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Orgovyx	Relugolix	66	1,946	$177,439
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	20	149	$464
Dexamethasone	Dexamethasone	13	366	$313
Oxycodone Hcl	Oxycodone Hcl	13	171	$121
Lorazepam	Lorazepam	21	24	$16

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
B4034	Enteral feeding supply kit; syringe fed, per day, includes but not limited to feeding/flushing syringe, administration set tubing, dressings, tape	N	N/R	25	$1,022

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	59	$36,742	Myriad Genetic Laboratories, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Christopher Melvin Lee, M.D.?

Tedicare shows public-source Medicare data for Christopher Melvin Lee, M.D. (NPI 1043266810), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Christopher Melvin Lee, M.D. have ACO affiliation data?

Christopher Melvin Lee, M.D. is shown with ACO affiliation data for Kootenai Accountable Care, LLC (MSSP, ACO ID A3621), Caravan Collaborative Pathways (MSSP, ACO ID A4604), and Collaborative ACO 30, LLC (MSSP, ACO ID A5483).

What billing organization is linked to Christopher Melvin Lee, M.D.?

Christopher Melvin Lee, M.D. is linked to CANCER CARE NORTHWEST CENTERS P S (billing NPI 1922072081) in the available physician profile data.

Does Christopher Melvin Lee, M.D. have Open Payments data?

Christopher Melvin Lee, M.D. has 59 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.